	US 12,435,145 B2
	B7-H4 antibody formulations
Yong Quan, South San Francisco, CA (US); Chin-Yi Huang, South San Francisco, CA (US); and Harjeet Singh Ganda, South San Francisco, CA (US)
Assigned to Five Prime Therapeutics, Inc., Thousand Oaks, CA (US)
Filed by Five Prime Therapeutics, Inc., South San Francisco, CA (US)
Filed on Aug. 19, 2020, as Appl. No. 16/997,577.
Application 16/997,577 is a continuation of application No. PCT/US2019/018965, filed on Feb. 21, 2019.
Claims priority of provisional application 62/633,537, filed on Feb. 21, 2018.
Prior Publication US 2021/0070861 A1, Mar. 11, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01)

CPC C07K 16/2827 (2013.01) [A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 2039/505 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/565 (2013.01); C07K 2317/94 (2013.01)]

19 Claims

1. A pharmaceutical composition comprising (i) an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4 and comprises the VH CDR1, VH CDR2, VH CDR3 and VL CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 5-10, respectively, (ii) a buffer, and (iii) a pH of about 4.5 to about 6.